Benefit-risk assessment: to quantify or not to quantify, that is the question-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Benefit-risk assessment: to quantify or not to quantify, that is the question

Published:2011-04-27 Issue:6 Volume:20 Page:653-656
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Yuan Zhong¹,Levitan Bennett¹,Berlin Jesse A.

Affiliation:

1. Epidemiology; Johnson and Johnson Pharmaceutical Research and Development; Titusville NJ USA

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.2149/fullpdf

Reference23 articles.

1. AstraZeneca Receives Action Letter From FDA for Exanta (ximelagatran) http://www.drugs.com/nda/exanta_041008.html

2. Merck Announces Voluntary Worldwide Withdrawal of VIOXX® http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf

3. ESAs further restricted, but debate continues;Brower;J Natl Cancer Inst,2008

4. Safe drugs and the cost of good intentions;Eichler;N Engl J Med,2009

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The assessment of patient clinical outcome: A literature discussion;Annals of Tropical Medicine and Public Health;2017

2. Benefit–Risk of Therapies for Relapsing–Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis;CNS Drugs;2016-08-18

3. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone;Pharmacoepidemiology and Drug Safety;2015-09-16

4. Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment;International Journal of Methods in Psychiatric Research;2014-07-03

5. Benefit–risk assessment and public communication;Therapeutic Risk Management of Medicines;2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3